In a post hoc analysis of the CAUGHT-CAD randomized trial, 338 asymptomatic, statin-naive, intermediate-risk adults (mean age 58) underwent coronary CTA at baseline and three years. Across 840 lesions, statin treatment tracked with regression of noncalcified plaque (β = -9.83, P < 0.001) and greater growth in intermediate-density (β = 0.89) and high-density calcium (β = 0.79), independent of risk factors and LDL-C. Participants achieving at least 30% LDL-C reduction also gained very high density calcium.
This result helps explain a long-standing paradox: statins lower events yet often raise coronary artery calcium scores. The answer appears to be density, not just volume. Dense calcium is biologically inert and less prone to rupture, while soft, lipid-rich plaque drives most heart attacks. A rising calcium score on a statin may therefore signal stabilization rather than failure, which matters for anyone tempted to repeat calcium scoring and misread an increase. The dose-response with LDL-C lowering reinforces the case for hitting meaningful targets rather than merely prescribing.
Caveats are real. This was a post hoc, lesion-level analysis, and statin use was not the randomized contrast in the way a dedicated trial would be, so confounding by adherence or baseline differences remains possible. No hard clinical events were tested, so density is a plausible surrogate, not a proven mediator of benefit. Earlier work, including the PARADIGM and GLAGOV-era imaging studies, points the same direction, making this a confirmatory advance that sharpens how we interpret imaging rather than overturning practice.